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Abstract
Background: Respiratory syncytial virus (RSV) is one of the most important causes of pediatric hospital admissions
in the developed world. The ribonuclease Dicer is an important regulator of gene expression and cellular function
via RNA interference, and may also have anti-viral functions. A previous microarray analysis of the cord blood of
5 patients with RSV disease suggested downregulation of Dicer. In order to further investigate whether reduced
Dicer expression can predispose newborns to RSV disease, we have analyzed the gene expression of Dicer in the
cord blood of 37 infants with confirmed RSV disease.
Methods: The cord blood of 2108 newborns was collected. 51 had a positive nasopharyngeal aspirate for RSV <1
year, and were grouped according to disease severity. 37 had sufficient cord blood RNA of good quality. Dicer
gene expression was assessed by qPCR analysis of cord blood using a TaqMan low-density array and compared to
control infants who did not present with RSV disease using the Mann-Whitney test.
Results: There was significant downregulation of Dicer in the severe disease group: relative quantity 0.69 (95% CI:
0.56 - 0.87), p = 0.002. There was no significant downregulation in the mild disease group.
Conclusions: We demonstrate reduced Dicer expression in the cord blood of infants with severe RSV disease, prior
to RSV exposure. We theorize that this may predispose to RSV disease by disruption of leukocyte gene regulation
or direct anti-viral RNA interference mechanisms.
Background
Bronchiolitis and other lower respiratory tract diseases are
amongst the most common causes of pediatric admissions
[1,2]. In epidemiological studies the most important
pathogen causing bronchiolitis has consistently been
respiratory syncytial virus (RSV) [1,3-7]. The yearly epi-
demics of RSV lead to a significant increase in admissions
to pediatric wards across the globe during the winter and
spring months. Infantile RSV bronchiolitis is associated
with later development of asthma in childhood [8], and is
therefore a major cause of ongoing disease burden to
patients and significant health costs to society [5].
69% of US children are infected with RSV in the first
year of life, and almost all by the age of two years [6].
The majority are asymptomatic or have only mild
symptoms. International studies estimate the annual
incidence of RSV bronchiolitis requiring hospital admis-
sion to 22 - 31/1000 amongst infants < 1 year [2,6,9,10].
Why so few children exposed to RSV should develop
symptoms requiring hospital admission is yet to be ade-
quately explained, although research has provided impor-
tant clues in the last 10 years. Some genetic associations
with RSV infection have already been described [11-15]
and predisposition to RSV bronchiolitis is likely to be
multifactorial. Increased knowledge about the pathophy-
siology of bronchiolitis and predisposing factors will aid
researchers in the development of preventative measures
and therapies for bronchiolitis [16,17].
Dicer is an RNase III enzyme that produces micro
RNA (miRNA) sequences by cleaving nuclear derived
pre-miRNA. miRNA interferes with gene expression by
binding to complementary mRNA, facilitating mRNA
degradation and preventing mRNA translation into pro-
tein. This mechanism is called RNA interference
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(RNAi), and is an important post-transcriptional regula-
tor of gene expression [18,19]. There is good evidence
to suggest that RNAi also has a direct anti-viral func-
tion. Cellular derived miRNA has specific antiviral
effects, interfering with viral gene expression [20-22].
Dicer can also cleave long genomic viral dsRNA
sequences into short interfering RNA (siRNA). siRNA
can thus be virally derived and have perfect sequence
specificity for viral mRNA. While this is a specific anti-
viral mechanism in plants and invertebrates, there is
currently no evidence to suggest that this is true for
mammals, in which the interferon system is more
important in viral defense [20,22]. However, synthesized
siRNA tailored to specific viruses has been shown to
have significant anti-viral effects in humans, in an inter-
feron-independent manner [23,24].
We have previously investigated gene expression by
microarray analysis of the cord blood of 5 infants who
later developed RSV bronchiolitis [25]. Unpublished
results of this study include a tendency to downregulation
of Dicer in these infants. Our hypothesis is that reduced
Dicer expression at birth predisposes newborns to RSV
disease, and to investigate this we have analyzed Dicer
expression in the cord blood of 37 infants with confirmed
RSV infection.
Methods
Collection of cord samples
The Akershus Birth Cohort Biobank was established
between January 2003 and February 2004 [25]. From a
total of 3500 births at our hospital, the cord blood of 2108
infants was collected. Samples were collected into Pax-
Gene RNA collection tubes (PreAnalytiX), and EDTA
tubes. EDTA tubes were centrifuged and a cellular layer
with the intention of later DNA analysis was removed. All
samples were stored at -80°C. The study was approved by
the Regional Norwegian Ethics Committee and we have
informed, written maternal consent.
Identification of RSV infection
On clinical examination in our pediatric emergency unit,
nasopharyngeal aspirates (NPAs) were taken routinely in
all patients with suspected viral respiratory disease.
NPAs were taken by deep nasal suctioning followed by
the aspiration of 2 ml viral transport medium and analy-
sis with an RSV rapid antigen test (Abbott TestPack
RSV, Abbott laboratories) [26]. If negative, the NPA was
analyzed for RSV by multiplex RT-PCR (Prodesse, Inc)
[27]. All virological tests were conducted at the Depart-
ment of Microbiology, Akershus University Hospital.
Patient identification and clinical information
Patients were defined as those with a positive rapid anti-
gen test or PCR of their NPA for RSV before 1 year of
age. To identify these infants, we cross-referenced our
cohort with the hospital’s microbiological database.
Patient medical records were reviewed and clinical data
pertaining to the episode of RSV disease retrieved. 17
healthy controls were randomly selected from the cohort
of 2108 infants, and their medical records appraised for
respiratory or other disease, or testing for RSV in the first
3 years of life. Patients and controls were excluded if they
had conditions predisposing to RSV bronchiolitis (anato-
mical anomalies including congenital heart disease and
cleft palate; prematurity before week 34; chronic lung dis-
ease; known or suspected genetic or neurological deficits,
including Down’s syndrome and hypotonia) [9,28,29] or
conditions which could significantly alter gene expression
at birth (perinatal viral or bacterial infection; small for
gestational age, defined as < 10th percentile for weight).
Controls were also excluded if they moved from our hos-
pital’s population area, were admitted to hospital with
respiratory diseases (including bacterial or viral infec-
tions, asthma, or other chronic lung conditions), or were
positive for RSV before 3 years of age. In order to investi-
gate differences in gestational or delivery factors that
might alter gene expression, we reviewed maternal medi-
cal records for delivery method, birth weight, Apgar
score and placental weight.
6 patients were treated for RSV by their general practi-
tioner (GP), and were not admitted to hospital. Similarly,
most of the controls had not been admitted to hospital
other than for orthopedic conditions. We do not have
clinical data for these patients and controls other than
age at which they were tested, the fact that they were not
admitted to our hospital, and birth data. We have con-
firmed that they were not admitted for treatment at
other pediatric units in our region by contacting the
archives unit at each hospital.
Disease definition and classification
We defined RSV disease as a positive NPA for RSV irre-
spective of symptoms. The patients were categorized into
mild or severe RSV disease according to a pre-determined
algorithm (table 1). The data most consistently recorded
in our patients’ medical records were use of respiratory
support, supplemental oxygen, feeding tubes, intravenous
fluids, and the pediatrician’s assessment of respiratory
effort, including severity of retractions. The disease cate-
gorization algorithm was constructed using these data.
Importantly, liberal admission practice meant that a num-
ber of neonates with mild disease were admitted for obser-
vation, and we wanted to ensure that these infants were
not classified with severe disease simply on the basis of
their admission to hospital. Investigators were blinded to
patient Dicer status when determining disease classifica-
tion. Patients tested for RSV by their GPs, but not referred
for admission at this or other nearby hospitals, were
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considered to have mild disease since referral was presum-
ably not necessary.
Preparation of samples for analysis and RNA quality
Total RNA was extracted using PAXgene blood RNA
isolation kit (PreAnalytiX) with DNase treatment
according to the manufacturer’s instructions. The quan-
tity of total RNA was assessed using the NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies).
RNA quality was assessed by the RNA integrity number
(RIN), determined using the Agilent 2100 Bioanalyzer
with RNA 6000 nanochips (Agilent Technologies). RNA
purity was good, with a mean 260/280 ratio 2.05 (SD
0.04; range1.9-2.1); mean 260/230 ratio 1.99 (SD 0.2;
range1.4-2.3); and mean RIN 7.8 (SD 0.7; range 4.7 -
9.2). A No-RT control experiment showed high amounts
of genomic DNA in our RNA samples prior to conver-
sion to cDNA. To avoid detection of genomic DNA, we
selected a probe that spans an exon junction (DICER1-
Hs00229023_m1, Applied Biosystems).
Selection of reference gene
A defective TLDA card sealer resulted in a number of
wells not sealing correctly during the qPCR experiment,
and there was inadequate amplification in all samples.
This affected the 3 selected reference genes, but not
Dicer. The qPCR experiment was run simultaneously
with another gene expression investigation including
ICAM2 (probe: ICAM2-Hs00168384_m1, Applied Bio-
systems). Mean ICAM2 non-normalized cycle threshold
(Ct) was 25.1 (SD 0.43) for the control group, 25.2 (SD
0.5) for the mild RSV group and 25.1 (SD 0.45) for the
severe RSV group. Importantly, the Mann-Whitney test
revealed no significant differences in ICAM2 Ct values
between the patient and control groups (p = 0.987). We
were thus able to identify ICAM2 as a suitable reference
gene, and all samples were normalized against ICAM2.
qPCR analysis
The patient and control samples were prepared accord-
ing to standard guidelines for qPCR experiments
(Applied Biosystems): 1 μg total RNA was reverse tran-
scribed using the High Capacity RNA to cDNA Master
Mix (Part Number 4390777, Applied Biosystems) and
cDNA was added to high molecular grade water to a
total volume of 52.5 μl and stored at -20°C. 52.5 μl Taq-
Man Gene Expression Master Mix was added to the
cDNA sample before loading 100 μl to each LDA fill
port. Loading, centrifuging and sealing of the TaqMan
array was done according to the manufacturer’s instruc-
tions. The plate was run on the ABI PRISM 7900 HT
with TaqMan Array thermal cycling block and the ther-
mal profile: 50°C for 2 min, 94.5°C for 10 min and 45
cycles at 97°C for 30 seconds and 59.7°C for 1 min. ABI
Prism SDS2.3 software and RQ Manager 1.2 (Applied
Biosystems) was used to process qPCR results.
There was amplification of Dicer mRNA in 16 of 17
control samples and in all patient samples. Mean non-
normalized Dicer Ct = 27.1 (SD 0.71; range 3.3). Dicer
Ct values were normalized against the reference gene,
and then calibrated against the median of the control
group, according to the ΔΔCt method [30,31]. The
ΔΔCt scale is a 1/log2 scale: doubling the quantity of
mRNA in a sample will result in a reduction of the
ΔΔCt by 1. Relative quantities of mRNA were therefore
calculated using a (2-ΔΔCt) transformation.
Protein analysis
The cellular samples from our cohort were tested for
Dicer by Western blot analysis in a selection of samples
from our cohort (method described below). We were
unable to demonstrate Dicer in our samples. To investi-
gate whether our samples were corrupted, we repeated
the procedure in new cord blood samples from infants
born June 2010, in adult blood samples and in protein
isolated from a colorectal adenocarcinoma cell line,
WiDr (ATCC Number CCL-218, LGC Standards).
New cord and adult blood samples were collected in
EDTA tubes, centrifuged and the WBC layer sampled.
Contaminating red blood cells were treated with FACS
lysing solution before centrifugation, wash and a new
centrifugation to pellet the WBCs. WiDr cell mono-
layers were harvested by scraping into PBS stored at 4°C
and centrifuged at 3,000 g at 4°C for 5 min. All samples
were stored at -80°C.
Proteins were isolated using Mammalian Protein Extrac-
tion Reagent (M-PER, Thermo Fisher Scientific). Halt Pro-
tease Inhibitor Cocktail, Halt Phosphatase Inhibitor
Cocktail (WiDr cells) and EDTA Solution (Thermo Fisher
Scientific), were added to the M-PER just before use.
100 μl lysis buffer per well (9,6 cm2) was used for the
WiDr cell line and homogenates were rotated for
Table 1 Patient classification algorithm
SEVERE DISEASE MILD DISEASE
Respiratory Support (CPAP or Mechanical
Ventilation)
Not admitted
Apnea related to respiratory exhaustion Upper respiratory disease
only
Oxygen requirement Mild or no Dyspnea1
Cardiovascular compromise2
Feeding tube or intravenous fluids
Significant Dyspnea1
Note: Patients are classified as having severe or mild RSV disease if they
display one of the characteristics in the respective columns. In the event a
patient had characteristics from both columns, the patient was classified with
severe disease. CPAP: Continuous positive airways pressure.
1Pediatrician’s assessment of respiratory effort.
2Defined as mottled, grey appearance with pulse > 170, reduced
consciousness and clinical response to intravenous bolus of 0.9% saline.
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60 min at 4°C and centrifuged (15,000 g for 30 min at 4°
C). We used 500 μl lysis buffer per 100 μl Cohort sam-
ple and 100 μl lysis buffer on the WBC pellet from
adult and new cord samples. Samples were shaken at
750 rpm on an Eppendorf thermomixer for 60 min at
4°C and centrifuged at 14,000 g for 30 min at 4°C. The
supernatant was transferred to a new tube for analysis.
The extracted protein from new cord blood samples was
vacuum centrifuged to achieve sufficient total protein
concentrations. 200 μl of some of the cohort samples
were sonicated at 10% amplitude on the Branson digital
sonifier for 10 sec. Total protein was determined by
proteinA280 on the NanoDrop ND-1000 Spectrophot-
ometer. Samples were stored at -80°C.
Western blot analysis for Dicer was performed using 2
Dicer antibodies (Cell Signaling Technologies, product
number 3363; and Abcam, product number ab14601) in
separate experiments. In the qPCR analysis, our mRNA
probe has affinity for the 2 major Dicer transcript var-
iants [GenBank: NM_030621 and NM_177438], and 4
alternative splice variants [GenBank: AB_028449,
AB_023145, AJ_132261, and BC_150287] [32]. Our anti-
bodies have specificity for the 2 major variants and all
alternative variants except for BC_150287.
Samples were denatured at 95°C for 5 min. Gel load-
ing quantities were: 50 μg WiDr protein; 50 μg adult
WBC protein; 50 μg and 150 μg new cord WBC protein
and cohort protein. The samples were resolved in 4-20%
Linear gradient SDS-PAGE, Criterion Tris-HCl gels
(BioRad) and immunoblotted onto PVDF membranes
(GE Healthcare). Membranes were blocked in 5% non-
fat dried milk in 1x Tris Buffered Saline containing 0.1%
Tween20 (1x TBS-T) (BioRad) at room temperature for
1 h and incubated overnight at 4°C with Dicer primary
antibody in 1x TBS-T. After washing, the membranes
were incubated with secondary antibody in 5% non-fat
dried milk in 1x TBS-T for 1 h at room temperature.
The blots were visualised by ECL Plus Western blotting
detection system (GE Healthcare) according to the sup-
plier’s instructions. Membranes were visualised on the
LAS-3000 mini (Fujifilm Corporation).
We were unable to demonstrate Dicer in our cohort
samples, the new cord blood samples or adult blood
samples. Dicer was clearly demonstrated in the WiDr
cells.
Statistical analysis
A power analysis of our previous microarray results
[25] indicated a need for 11 individuals in each group
in order to achieve a power of 80%. qPCR results were
analyzed using the Mann-Whitney test. The median
difference between groups was calculated using the
Hodges-Lehmann estimator, first calculated for the
normally distributed ΔΔCt values, and then converted
to relative quantities. For graphical presentation, ΔΔCt
values were assigned a negative value so that a lower
value represents less Dicer mRNA. Patient clinical
characteristics were analyzed using Student’s t-test and
ANOVA for normally distributed parameters, the
Mann-Whitney test for non-normally distributed para-
meters, and the chi-square and Fisher’s exact test for
categorical parameters. Statistical analyses were carried
out using PASWstatistics 17.0 and Minitab 15.0 statis-
tical software. Using a Bonferroni correction to allow
for other qPCR experiments carried out concurrently
with this investigation, we considered p < 0.005 to be
statistically significant for differences in Dicer expres-
sion, p < 0.025 to be significant for epidemiological
characteristics, and p < 0.05 to be significant for clini-
cal characteristics.
Results
We identified 52 infants from our cohort who tested
positive for RSV before 1 year of age. One had cleft
palate and was excluded; otherwise there were no
patients who met exclusion criteria. Due to use of RNA
in previous experiments, 37 had sufficient RNA for ana-
lysis. 20 were classified with severe RSV disease and 17
with mild RSV disease. 4 infants with mild disease
included in the final analysis were diagnosed by their
GP and not sent to hospital. The clinical findings for all
identified patients are summarized in tables 2 - 3. There
were no significant differences in clinical characteristics
between the 14 patients not included, and the 37
included in the qPCR experiment (data not shown).
Dicer Gene Expression
There was significant downregulation of Dicer in the
severe disease group (p = 0.002). There was no signifi-
cant downregulation in the mild disease group (p =
0.48). Results are demonstrated in table 4 and figure 1.
When comparing the severe disease group to the mild
disease group, there was a tendency to significance (p =
0.034), when corrected by Bonferroni’s method.
Discussion
In this experiment we find significantly reduced levels of
Dicer mRNA in the cord blood of infants who later
develop severe RSV disease when compared to controls.
This result was not apparent in infants who developed
mild RSV disease. The severe disease group tended
towards reduced Dicer mRNA when compared to the
mild disease group. In our cohort, none of the patients
with RSV disease required mechanical ventilation or
CPAP, the most severe form of the disease. Thus, our
findings reflect on the more usual group of patients
with significant dyspnea requiring hospital admission
but not mechanical respiratory support. There was a
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Table 2 Epidemiological and birth data for control, mild RSV and severe RSV groups
CONTROL MILD DISEASE SEVERE DISEASE Sig.
Number 16 17 20 -
Median age on admission (IQR), months - 3 (2 - 4) 2.5 (1.00 - 5.75) p = 0.661
Male: Female ratio 8 : 8 9 : 8 10 : 10 p = 0.982
Vaginal Delivery:
Non-Instrumental 14 82% 12 71% 17 85%
Instrumental 2 12% 2 12% 1 5%
Caesarian Section: p = 0.343
Elective 0 0% 1 6% 2 10%
Emergency 0 0% 2 12% 0 0%
Mean Gestational Age (S.D.), weeks 39.6 (1.5) 39.1 (2.1) 39.3 (1.5) p = 0.544
Mean Birth Weight (S.D.), grams 3628 (590) 3910 (815) 3617 (517) p = 0.884
Mean placental weight (S.D.), grams 629 (140) 832 (228) 721 (199) p = 0.0085
1 min Apgar < 8 0 (0%) 3 (18%) 1 (5%) p = 0.143
5 min Apgar < 8 0 (0%) 1 (6%) 0 (0%) p = 0.343
Note: There was a higher placental weight in the mild disease group compared to controls, but not in the severe disease group. Otherwise, there were no
significant differences in gestational or delivery factors that might affect gene expression. Patients in mild and severe groups were ill at similar ages. 1Mann-
Whitney test; 2Fischer’s exact test; 3chi-square test; 4ANOVA.
5For mild disease vs. control p = 0.008; for severe disease vs. control, p = 0.205 (Student’s t-test).
Table 3 Clinical features and diagnoses of 37 infants with confirmed RSV disease
MILD DISEASE SEVERE DISEASE Sig.
Number 17 20 -
CLINICAL FEATURES:
Significant Dyspnea1 0 (0%) 17 (85%) -
Apnea 0 (0%) 2 (10%) -
Cardiovascular Compromise 0 (0%) 2 (10%) -
Highest pCO2, mean (S.D.), kPa 5.83 (0.93) 6.70 (1.88) p = 0.0882
Lowest O2 saturation; mean (S.D.), % 98 (2.4) 93 (5.9) p = 0.005
2
Highest Respiratory Rate; Mean (S.D.),/min 40 (9.7) 50 (8.3) p = 0.0032
Pulse on admission; mean (S.D.),/min 153 (18) 155 (18) p = 0.8062
Weight on admission; mean (S.D.), grams 6470 (1613) 6640 (1910) p = 0.822
Duration of symptoms on admission; mean (S.D.), days 4.5 (3.4) 4.1 (1.3) p = 0.622
Length of stay; median (IQR), days 2 (2 - 4) 5 (3 - 5) p = 0.0013
INTERVENTIONS
CPAP/Ventilator 0 (0%) 0 (0%) -
Supplemental Oxygen 0 (0%) 8 (40%) -
Supplemental Fluids
Intravenous 0 (0%) 2 (10%) -
Feeding Tube 0 (0%) 3 (15%) -
CLINICAL DIAGNOSIS:5
Bronchiolitis 12 (71%) 20 (100%)
Pneumonia 1 (6%) 2 (10%)
Atelectasis 0 (0%) 2 (10%) p = 0.4074
URTI 1 (6%) 0 (0%)
Uncertain Diagnosis6 4 (24%) 0 (0%) -
Note: There was a statistically significant reduction in oxygen saturation, increase in respiratory rate and longer length of stay in the severe disease group, and a
tendency to higher pCO2. Clinical features, interventions and diagnoses incorporated in the algorithm for disease severity were not analyzed statistically. pCO2:
capillary partial pressure of carbon dioxide; URTI = Upper respiratory tract infection.
1Pediatrician’s assessment of respiratory effort.
2Student’s t-test; 3Mann-Whitney test; 4chi-square test.
5Some patients received more than one diagnosis, e.g.: bronchiolitis and atelectasis.
64 patients tested for RSV by GPs, but not referred to hospital, received an uncertain diagnosis. An inquiry of hospital archives reveals that these patients have
not been admitted at other pediatric clinics in our region.
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larger placental weight in the mild disease group com-
pared to control. There is no evidence in the literature
to suggest that this difference would affect our results
significantly, and by experience a larger placental weight
would be of benefit in otherwise healthy children.
Otherwise, we did not identify any differences between
the groups at birth that might affect gene expression.
There were significant variations in oxygen saturation,
respiratory rate and length of stay between the mild and
severe RSV groups, and a tendency to increased pCO2
in the severe group, supporting the legitimacy of our
disease classification algorithm. To our knowledge this
is the first experiment specifically investigating the role
of Dicer in RSV disease.
Our selection of controls and classification into mild
or severe disease was retrospective and required some
assumptions about patients who had not been examined
at our hospital for respiratory disease. This includes all
the controls and 4 of those with mild disease tested for
RSV by their GP, but not referred to hospital. This
introduces the possibility of misclassification by several
mechanisms: controls may have had RSV disease but
not been tested, or may not have visited their GP at all;
4 infants not sent to hospital were assumed to have
mild disease, but may have had severe disease; we rely
on accurate completion of medical records; there may
have been inter-observer variation in the pediatrician’s
assessment of the severity of dyspnea. Given that 69% of
children are infected with RSV in the first year of life
[6], it is in fact likely that a number of the controls had
RSV disease, but only had mild symptoms (e.g.: rhinitis).
Therefore, it is not surprising that we do not show a dif-
ference between mild and control groups. Increasing the
number of control infants included in the analysis
would have increased the power of the study and there-
fore the chance of discovering a difference between con-
trol and mild groups. However, we feel that the groups
were so similar that any difference is not likely to be
clinically relevant. Patients with unrecognized severe dis-
ease included in the control or mild disease group may
increase the risk of type 1 or type 2 errors when consid-
ering the severe disease group. However, given our
experience with the patient population and GPs in our
area, we consider that the chance that infants with
severe disease would not visit their GP or be referred
for admission is small. Altogether, we had a low number
of patients in our analysis. Increasing the size of the
birth cohort may have increased the total number of
patients, the power of the study and the chance of dis-
covering a significant difference between mild and
severe disease groups.
Dicer protein was below detection level by Western
blot analysis of cord samples from our cohort. This
seems remarkable given that the qPCR experiment
showed high amounts of Dicer mRNA. Our antibodies
are also specific for proteins translated from the com-
monly occurring splice variants identifiable by our
Table 4 Relative quantities of Dicer mRNA in 17 infants
with mild and 20 infants with severe RSV disease,
compared to 16 controls
RELATIVE QUANTITY (95% CI) Sig.
Mild RSV disease 0.89 (0.67 - 1.23) p = 0.481
Severe RSV disease 0.69 (0.56 - 0.87) p = 0.0021
Note: The median difference and confidence intervals between patient and
control groups was calculated using the Hodges-Lehmann estimator for ΔΔCt
values, and a 2-ΔΔCt transformation to generate relative quantities. Statistical
analysis was done using the Mann-Whitney test. There was significant
downregulation of Dicer in the severe RSV group but not in the mild RSV
group.
1Mann-Whitney test.
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Figure 1 Dicer gene expression in cord blood. A: Dicer cord blood gene expression in control and patient groups. Median values with 95% CI.
p = 0.002 for severe RSV disease vs. control. B: Dicer expression in the cord blood of 20 patients with severe RSV disease, compared to the
median of the control group. A negative value represents reduced expression.
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mRNA. We corroborated our primary antibodies and
Western blot technique by demonstration of Dicer in
colorectal cancer cells. We encountered the same phe-
nomenon in new cord and adult peripheral blood leuko-
cyte samples, so degradation of Dicer protein in our
cohort samples seems an unlikely explanation. Dicer is
essential for, and miRNA profiles are well described in,
normal leukocyte function, development and prolifera-
tion [33]. We can therefore not explain why Dicer
protein was not detectable in our samples. To our
knowledge, Dicer has not previously been demonstrated
by Western blot analysis in human leukocytes. One
could speculate that peripheral blood leukocytes contain
other splice variants of Dicer detected by our mRNA
probe but not by our antibodies; that leukocyte Dicer is
bound to other proteins and therefore not detected in
our blots; or that a different Dicer protein is active in
leukocytes, but we find no literary reports to confirm
this. It may be that Dicer mRNA is not transcribed to
Dicer protein or the protein is rapidly degraded once
produced, but given the necessity for Dicer in leuko-
cytes, this seems unlikely. We can, however, not exclude
variations in post-transcriptional modification, and we
are unable to measure whether there are differences in
Dicer protein level between patients and controls. Thus
we cannot verify that the difference we see in Dicer
mRNA level reflects a real difference in Dicer protein
level in our cohort. However, several articles investigat-
ing Dicer gene expression in cancer have found a good
correlation between Dicer mRNA level and Dicer pro-
tein level [34-36], and Dicer mRNA level as a proxy for
Dicer protein level therefore seems reasonable.
In cord blood, the main source of mRNA should be
nucleated cells, primarily myeloid and lymphoid leuko-
cytes. The functional effect of Dicer downregulation in
these cells is likely to be two-fold: disrupted cellular
function, and reduced direct anti-viral activity. In mur-
ine models, absence of Dicer leads to considerable dis-
ruption of cell function in T-lymphocytes, natural killer
cells and Langerhans cells [37-40]. In alveolar cell cul-
tures, influenza virus mediated Dicer downregulation
coincides with significantly accelerated cell death [21].
In humans, reduced Dicer mRNA levels have been asso-
ciated with hepatocellular carcinoma, invasive epithelial
ovarian cancer and metastatic breast cancer [34-36], and
it is likely that disruption of miRNA mediated gene reg-
ulation plays a role in cancer development [33]. It is
thus clear that not only the absence of, but also downre-
gulation of Dicer results in disruption of cellular activity.
The immune response to RSV in infants is primarily dri-
ven by the innate immune system until the point of maxi-
mal symptoms, at which time recruitment of the cellular
immune response hastens viral clearance [17,41] and clini-
cal improvement. In leukocytes, Dicer downregulation in
an anti-RSV setting would likely be most significant in the
myeloid and natural killer cells, as they survey the lung
environment, identify antigen and regulate the innate
immune response to RSV. On recognition of viral antigen,
myeloid dendritic cells recruit neutrophils and macro-
phages, and migrate to lymphoid tissue where they activate
a cellular immune response [17,42]. Impairment of innate
immune cellular function in association with Dicer down-
regulation in our patients may thus disturb the innate
response to RSV and likely delay the recruitment of TH1
helper cells, which may also be dysfunctional [37].
The Dicer-mediated production of endogenous anti-viral
miRNA may also be reduced in our patients. In an investi-
gation of the role of Dicer in influenza, in-vitro knock-
down of Dicer to a functional level of 30% in human
alveolar cells resulted in increased influenza virus replica-
tion and greater apoptosis rates [21]. These were interest-
ing results, and it is tempting to hypothesize that Dicer
downregulation would similarly result in greater RSV viral
load in our patients. This could result in increased apopto-
sis, greater activation of the immune response, more air-
ways inflammation and therefore more severe disease.
However, blood leukocytes and human alveolar cells are
quite different cells types, and we therefore cannot assume
that our results reflect Dicer expression levels in lung tis-
sue. Our experiment was not designed to investigate the
state of pulmonary epithelial cells in infants prior to RSV
exposure, and such an experiment is currently not feasible
due to ethical and practical issues.
RNAi as an anti-viral therapy currently receives much
interest, and synthetic siRNAs with tailored activity
against HIV, hepatitis B virus, human metapneumovirus
and RSV are under development [24,43-45]. ALN-
RSV01 (Alnylam Pharmaceuticals) is a synthesized
siRNA with activity against the RSV N-protein [24]. In
a recent trial, ALN-RSV01 was administered intra-
nasally to adults before and after nasal inoculation with
RSV. There was a significant anti-viral effect, with fewer
patients RSV-culture positive in the ALN-RSV01 group
compared to placebo [23]. In another trial, adult lung
transplant recipients with proven RSV infection were
randomized to nebulized ALN-RSV01 or placebo. The
ALN-RSV01 group had a lower nasal RSV load, an
improved symptom score, and a lower incidence of
bronchiolitis obliterans syndrome, a known complica-
tion of RSV infection in this patient group [46]. Our
findings suggest that infants susceptible to severe RSV
infection may have a reduced capacity to produce anti-
viral miRNA, strengthening the hypothesis that synthe-
sized anti-RSV siRNA will have clinically relevant effects
in lower respiratory RSV disease in infants. This is sig-
nificant, given that after 5 decades there are still no safe
and effective vaccines or treatments for RSV other than
prophylaxis [16].
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Our experiment was not designed to discover the
cause of Dicer downregulation, and future experiments
will be aimed at this. Genetic or epigenetic factors invol-
ving the Dicer gene or promoter may be at fault. In
addition, dysregulation of other molecular systems can
affect Dicer expression. A number of single nucleotide
polymorphisms in genes of the immune system are asso-
ciated with RSV [11], and we have previously shown
downregulation of TNF receptor 25 in infants with RSV
disease [25]. It is not clear how these factors would
affect Dicer expression. However, one in vitro study
showed that interferon-a downregulates and interferon-
g upregulates Dicer [47], suggesting that variations in
response to stress (e.g.: birth) may explain our findings.
Such differing stress responses could in themselves
explain the predisposition for RSV disease.
Conclusion
In summary, we demonstrate reduced Dicer expression
at birth in the cord blood of infants with severe RSV
disease, prior to RSV exposure. We theorize that this
may predispose to RSV disease by disruption of both
miRNA-associated gene regulation in leukocytes and
direct anti-viral RNA interference mechanisms. We can
thus add to the understanding of the pathophysiological
processes in severe RSV disease.
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